Kolon Life Science Inc. (KOSDAQ:102940)
South Korea · Delayed Price · Currency is KRW 31,500
-450 (-1.41%)
Aug 8, 2025, 3:30 PM KST
Kolon Life Science Company Description
Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products.
The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development.
It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products.
The company was formerly known as Korea Tissuegene Asia, Ltd. and changed its name to Kolon Life Science Inc. in January 2006.
Kolon Life Science Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Kolon Life Science Inc.
| Country | South Korea |
| Founded | 2000 |
| Industry | Medicinal Chemicals and Botanical Products |
| Employees | 426 |
| CEO | Sun Jin Kim |
Contact Details
Address: One & Only Tower Seoul South Korea | |
| Phone | 82 2 3677 4150 |
| Website | kolonls.co.kr |
Stock Details
| Ticker Symbol | 102940 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7102940004 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Sun Jin Kim | Chief Executive Officer |
| Sang-Jun Lee | Chief Operating Officer |